ArticleJournal of nanobiotechnology2026
Charge-flip nanoparticles loaded with TAK1 inhibitors inhibit retinal neovascularization.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Retinal neovascularization (RNV) is a key phenotype in multiple eye diseases that can cause blindness. Currently, the key treatment modality in RNV is the delivery of antivascular endothelial growth factor (anti-VEGF) medications via intravitreal injection, although the efficacy and adverse effects remain controversial. The aim of the present study was to investigate the influence of transforming growth factor-β (TGF-β)-activated kinase 1 (TAK1) and charge-reversal triblock nanoparticles loaded with a TAK1 inhibitor on the formation of retinal neovascularization. First, through bioinformatics analysis of retinal fibrovascular membranes from proliferative diabetic retinopathy (PDR) patients and healthy retinal tissues, we identified TAK1, a crucial inflammation-related gene. We developed a charge-reversal PLGA-PEI-DMMA nanoparticle delivery system (poly@NG25) loaded with a TAK1 inhibitor. Using oxygen-induced retinopathy (OIR) mouse models and human umbilical vein endothelial cells (HUVECs) combined with methods such as CCK-8, EdU, and flow cytometry, we explored the role and mechanism. TAK1 was found to drive pathological neovascularization via inflammatory and angiogenic mediators. Compared with NG25 alone, poly@NG25 accelerates drug release in acidic environments; inhibits HUVECs proliferation, migration, and tube formation, promotes apoptosis, and more effectively reduces RNV and lesions in OIR mice with enhanced drug retention through the regulation of regulating relevant inflammatory and angiogenic factors. This study confirms that TAK1 is a key RNV therapeutic target and presents a pH-responsive charge-reversal poly@NG25 system, offering mechanistic insight and a new strategy for improving retinal vascular disease treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.